[{"orgOrder":0,"company":"Two Cells","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"gMSC1","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Two Cells","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Two Cells \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Two Cells \/ Chugai Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Two Cells

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Upon termination of the Agreement, all domestic and foreign rights with respect to guaranteed Mesenchymal Stem Cell 1 (gMSC®1), a regenerative cellular medicine for chondrogenesis in the knee, granted to Chugai from TWOCELLS will be returned to TWOCELLS...

                          Brand Name : gMSC1

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 13, 2023

                          Lead Product(s) : gMSC1

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Sponsor : Chugai Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank